文献速递姑息放疗与转移瘤放疗物理与技术

放疗联合聚焦超声缓解癌症骨痛:IDEAL框架I/IIa期研究

Combining radiotherapy and focused ultrasound for pain palliation of cancer induced bone pain; a stage I/IIa study according to the IDEAL framework.
PubMed 文献 · Clin Transl Radiat Oncol · 2021-01-15

本研究为单臂R-IDEAL I/IIa期研究,纳入6例四肢骨、骶骨或胸骨症状性骨转移患者,先行外照射放疗(EBRT),4天内再行磁共振引导高强度聚焦超声(MR-HIFU)。联合治疗安全可行、耐受良好,7天时5/6患者报告疼痛缓解,4周时稳定在60%,无治疗相关严重不良事件。

要点

  • EBRT后4天内完成MR-HIFU在全部6例患者中后勤可行且耐受良好。
  • 联合治疗后7天5/6患者报告疼痛缓解,4周时稳定在60%。
  • 无治疗相关严重不良事件,但疗效是否优于标准EBRT需随机对照研究验证。

核心结论

  • 首次将EBRT与MR-HIFU联合用于癌症骨痛一线治疗,结果显示安全、可行且患者耐受良好。
  • 联合治疗在(疼痛缓解时间)和生活质量方面是否优于标准EBRT,需开展对比性(随机)研究评估。

研究设计与样本

  • 单臂、R-IDEAL I/IIa期研究,纳入6例在放射肿瘤科就诊、四肢骨及骶骨和胸骨存在症状性骨转移的患者。
  • 所有参与者接受EBRT,随后4天内接受MR-HIFU,评估安全性和可行性,并在联合治疗完成后4周内监测疼痛评分。

主要发现

  • 全部患者均能在EBRT后4天内按后勤安排计划并实施MR-HIFU治疗,且所有患者对联合操作耐受良好。
  • 联合治疗完成后7天,6例中5例报告疼痛缓解;4周随访时疼痛缓解稳定在60%。
  • 未发生治疗相关严重不良事件。

临床怎么用

  • 对于四肢骨、骶骨和胸骨症状性骨转移患者,可考虑EBRT后4天内联合MR-HIFU,但需在具备相应技术条件下开展。
  • 联合治疗期间应监测疼痛评分至治疗后4周,并关注治疗相关不良事件。

局限性

  • 单臂设计、样本量仅6例,无法与标准EBRT进行疗效比较。
  • 随访仅4周,长期疼痛缓解和生活质量数据未报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cancer induced bone pain (CIBP) strongly interferes with patient's quality of life. Currently, the standard of care includes external beam radiotherapy (EBRT), resulting in pain relief in approximately 60% of patients. Magnetic Resonance guided High Intensity Focused Ultrasound (MR-HIFU) is a promising treatment modality for CIBP. METHODS: A single arm, R-IDEAL stage I/IIa study was conducted. Patients presenting at the department of radiation oncology with symptomatic bone metastases in the appendicular skeleton, as well as in the sacrum and sternum were eligible for inclusion. All participants underwent EBRT, followed by MR-HIFU within 4 days. Safety and feasibility were assessed, and pain scores were monitored for 4 weeks after completing the combined treatment. RESULTS: Six patients were enrolled. Median age was 67 years, median lesion diameter was 56,5 mm. In all patients it was logistically possible to plan and perform the MR-HIFU treatment within 4 days after EBRT. All patients tolerated the combined procedure well. Pain response was reported by 5 out of 6 patients at 7 days after completion of the combined treatment, and stabilized on 60% at 4 weeks follow up. No treatment related serious adverse events occurred. CONCLUSION: This is the first study to combine EBRT with MR-HIFU. Our results show that combined EBRT and MR-HIFU in first-line treatment of CIBP is safe and feasible, and is well tolerated by patients. Superiority over standard EBRT, in terms of (time to) pain relief and quality of life need to be evaluated in comparative (randomized) study.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Bartels MMTJ, Verpalen IM, Ferrer CJ, et al. Combining radiotherapy and focused ultrasound for pain palliation of cancer induced bone pain; a stage I/IIa study according to the IDEAL framework. Clin Transl Radiat Oncol. 2021. PMID: 33532631. doi:10.1016/j.ctro.2021.01.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。